Report: Congressional Research Service Says DOJ Medical Marijuana Order Could Ease 280E, Research Barriers

A new report from the Congressional Research Service says the Department of Justice’s recent order rescheduling certain medical marijuana products to Schedule III could have major implications for state-licensed medical marijuana businesses, patients, researchers and federal tax policy.

The report analyzes DOJ’s April 23 final order, which moved marijuana and marijuana-derived products to Schedule III under the Controlled Substances Act when they are part of a Food and Drug Administration-approved drug product or subject to a state-issued medical marijuana license.

The change does not federally legalize marijuana and does not apply to adult-use marijuana. The CRS report notes that recreational marijuana activity would remain illegal under federal law even if marijuana were fully moved to Schedule III. However, it says the order may create a pathway for some medical marijuana operators to come into compliance with federal law for the first time.

Under the order, state-licensed medical marijuana manufacturers, distributors and dispensers can apply for federal DEA registration through a new expedited process. The order directs DEA to process applications submitted within 60 days within six months, while allowing early applicants to continue operating under their state-issued licenses while their applications are pending.

The report also highlights one of the most significant financial effects of the move: Section 280E of the Internal Revenue Code would no longer apply to state medical marijuana license holders covered by the order. That provision blocks businesses trafficking in Schedule I or II substances from taking standard federal business deductions. Because Schedule III substances are not covered by 280E, qualifying medical marijuana businesses could become eligible for deductions long denied to the industry.

CRS also notes that DOJ encouraged the Treasury Department to consider retrospective relief from 280E liability for tax years in which a business operated under a state medical marijuana license. The Treasury Department has said it plans to do so.

For patients, the report says DOJ’s order allows state medical marijuana certifications or similar documents to support dispensing, as long as they include the patient’s name and address, are dated and signed on the day they are issued, and identify the issuing practitioner. That means the order does not appear to require traditional CSA-compliant prescriptions for medical marijuana patients.

The report also says the order could make research easier by allowing researchers to obtain marijuana or marijuana-derived products from state-licensed sources without facing civil or criminal liability solely for doing so. However, CRS notes that marijuana-specific research requirements may still limit the practical impact of rescheduling.

CRS emphasizes that Congress still has broad authority to change marijuana’s status under federal law, including by rescheduling it, descheduling it or imposing stricter controls. The report also notes that DOJ has not finalized its broader proposal to move marijuana generally to Schedule III, with a new administrative hearing scheduled to begin June 29.

While the order is narrow, the report makes clear it could be one of the most consequential federal marijuana policy changes in decades, particularly for state-licensed medical marijuana operators that secure DEA registration.